Wugen Secures $115M to Lead AI-Driven Cell Therapy Innovation; U.S. Congressional Hearing Sparks Policy Outlook

1. AI Medical Financing Events

This week,AIThe medical track continued the high热度 from the first half of the year, with financing events mainly concentrated inMedical Service Platform, SpecialtyEHR、AIVoice Interaction, Cell Therapy, and Compliance GovernanceIn areas such as [...] while a simultaneous industry acquisition occurred. Overall, the financing scale ranged from several million to hundreds of millions of US dollars, including both early seed rounds and large-scale clinical-stage project financings.

1.AIDriven New Drugs and Therapies

• Wugen(St. Louis, USA)

Financing Amount:1.15Billion US dollars

Round: Undisclosed (Clinical Stage Financing)

Wugen, Inc. Founded in2018 Year, headquartered in St. Louis, Missouri, USA, is aClinical-stage biotechnology company dedicated to developing the next generation of ex vivo (off-the-shelf）CAR-T Cell Therapy for Hematologic Malignancies(Especially T Acute Lymphoblastic Leukemia and LymphomaSignificant Unmet Medical Needs。WugenIn8Month27Day announced completion1.15Million-dollar financing, byFidelity Management & ResearchLeading investment,RiverVest、Lightchain Capital、AbingworthAndTybourneand other institutions participated, the funds will be used to advance its“General”（allogeneic）CAR-TTherapyWU-CART-007The pivotal clinical trial is aimed at2027Year ApplicationFDAApproval.

• Leal Therapeutics(Boston, USA)

Financing Amount:3000Million USD

Round:ARound

Leal TherapeuticsFounded in2022Year, headquartered in Boston, USA,Focused on the development of treatments for schizophrenia,ALSNeurometabolic therapies for psychiatric and neurodegenerative diseases.The company announced on8Month27Day Completed3000Million USDARound of financing, bySV Health InvestorsUnder its umbrellaDementia Discovery FundLeading investment,OrbiMed、Newpath PartnersAndChugai Venture FundParticipate, etc. The funds will advance its pipelineLTX-001、LTX-002Entered the clinical stage, this is the company's first publicly disclosed financing.

2.Medical Digitalization and Service Platform

• Welcome Tech(Los Angeles, USA)

Financing Amount:750Million USD

Round: Strategic Financing

    Welcome TechFounded in2010Year, headquartered in Los Angeles, initially as a Latin community platformSABEResPODERStarting, it has currently developedTo connect immigrant communities with employment, healthcare, financial services, etc.AIDrive Super Platform. The company announced on8Month25Day Completed750Million USD in financing, byTTV Capital、Mubadala Capital、CityRock VenturesJoint investments will be used to accelerate platform construction and service expansion. PreviouslyWelcome TechAs of2021Year4Monthly Completion3500Million USDBRound of financing (SoftBank Opportunity Fund、TTV Capital、Owl VenturesLeading investment),2020Year CompletedALunyue800Million USD in financing, the earliest seed round can be traced back to2014Year.

• Barti Software(San Francisco, USA)

Financing Amount:1200Million USD

Round:AWheel

Barti SoftwareFounded in approximately2021Year, headquartered in San Francisco,Focused on providing for ophthalmic clinics and networksAIDriven Electronic Medical Records (EHR) and clinical workflow automation tools, to address the traditional generalEHRIn the inadequacies in high-frequency image processing and specialized data structures. The company, at8Month25Announced Completion on [Date]1200Million USDARound of financing, byFive Elms CapitalLed the investment. Although the investors have not been fully disclosed, the funding is clearly intended for product performance optimization and market expansion, particularly to enhance its automation and interoperability capabilities in ophthalmic diagnosis and treatment scenarios. This isBartiThe first disclosed financing round to date marks its accelerated layout in the digital ophthalmology track.

• Assort Health(San Francisco, USA)

Financing Amount:5000Million USD

Round:BRound

Assort HealthFounded in2019Year, headquartered in San Francisco, dedicated to the developmentAIA patient communication and voice automation platform driven by technology, helping healthcare institutions handle high-frequency tasks such as appointments, cancellations, and common inquiries.. The company announced on8Month26Day Completed5000Million USDBRound of financing, byLightspeed Venture PartnersLed the investment, the funds will be used to expand the team, extend the market, and enhance product functionality. Previously, the company had...2023Year CompletedARound of financing (approximately1500Million USD, investors includeGeneral Catalyst）。

• ALIGNMT AI(London, UK)

Financing Amount:650Million USD

Round: Seed Round

ALIGNMT AIFounded in2024Year, headquartered in London, UK, focusing onProviding for medical and life sciences institutionsAICompliance Model Library, Policy Mapping, and Automated Evidence Tracking Solutions, helping companies address increasingly stringent regulatory compliance requirements. The company8Month28Announced Completion on [Date]650Million USD Seed Round Financing, Investors IncludeLocalGlobeAndMMC Ventures, the funds will be used for product function expansion and sales network construction, marking its first financing.

3.M&A Events

• Battery VenturesAcquisitionEnzo Biochem(New York, USA)

  

  
  

Transaction Amount: Undisclosed

    Enzo BiochemFounded in1976Year, headquartered in New York, is a long-termA biotechnology company focusing on molecular diagnostics, research reagents, and clinical laboratory services。Battery VenturesIn8Month28Announced the completion ofEnzo BiochemThe privatization acquisition, after the completion of the transactionEnzoWill be delisted and become a non-public company in the futureBatteryPlans to leverage its brand and R&D foundation to drive product innovation and market expansion.

2. Policy Information

• U.S. Congress Accelerates HealthcareAIAgenda: Hearing or Pushing for Early Implementation of Regulatory and Payment Policies

      2025Year8Month27On the 18th, the U.S. House of Representatives Committee on Energy and Commerce issued a public notice, announcing that its health subcommittee will2025Year9Month3Day convened titled“Examining How Artificial Intelligence Technology Drives Transformation in U.S. Healthcare（Examining Opportunities to Advance American Health Care through the Use of Artificial Intelligence Technologies）”A special hearing; the announcement was issued by two committee chairs, aiming to hear from regulators, clinical institutions, industry representatives, and patient advocates at the congressional level.HealthcareAI(Including applications such as diagnostic support, administrative automation, payment and prior authorization processes) impact, risks, and policy needsThe testimony. The public announcement was made in8Disclosed in late August, indicating that the legislature will act in late summerMedicalAIIncluded in the Recent Supervision and Legislative Agenda——For enterprises,Congressional hearings often lead to faster discussions on regulatory or payment pathways.(For example,AIIn medical insurance/MedicareIn the application of payment and prior authorization, relevant enterprises, industry associations, and legal compliance teams should consider submitting written testimony or seeking to attend and speak to present their interests and risk management solutions in the congressional record.

• Rising Federal Interoperability and Compliance Pressures:AHAForwardASTPSurvey Promotes Industry Concentration Feedback

       2025Year8Month28Day, American Hospital Association (AHA) Published an Announcement on Its Official WebsiteASTP/ONCIn8Month26The notice for soliciting opinions released on the day encourages hospitals and health systems to participate in providing feedback. The article points out that this survey will assess information blocking andAPIThe reality problem of implementation,AHAClarified the timeline for submitting opinions and reminded members to pay attention to how the survey could impact future interoperability and compliance requirements.AHAReported in8Month28Publicly released on a daily basis, further amplifying the visibility of federal solicitations,It is expected to encourage more healthcare providers and healthITSupplier and Industry Organization in8End of the month to9Mid-month period concentrated towardsASTP/ONCProvide practical data and policy recommendations to influence regulatory pathways and industry compliance priorities in the short term.。